These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12969083)

  • 1. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome.
    Corazziari E; Bytzer P; Delvaux M; Holtmann G; Malagelada JR; Morris J; Muller-Lissner S; Spiller RC; Tack J; Whorwell PJ
    Aliment Pharmacol Ther; 2003 Sep; 18(6):569-80. PubMed ID: 12969083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entry criteria for drug trials of irritable bowel syndrome.
    Kamm MA
    Am J Med; 1999 Nov; 107(5A):51S-58S. PubMed ID: 10588173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irritable bowel syndrome and the Rome III criteria: for better or for worse?
    Gwee KA
    Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):437-9. PubMed ID: 17489052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between psychosocial parameters and outcome in irritable bowel syndrome.
    Creed F
    Am J Med; 1999 Nov; 107(5A):74S-80S. PubMed ID: 10588176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An approach to the design of therapeutic trials in IBS.
    Cann PA
    Scand J Gastroenterol Suppl; 1987; 130():67-76. PubMed ID: 3477017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of advertisement and clinic populations in symptoms and perception of irritable bowel syndrome.
    Lee OY; Fitzgerald LZ; Naliboff B; Schmulson M; Liu C; Fullerton S; Mayer EA; Chang L
    Aliment Pharmacol Ther; 1999 Dec; 13(12):1631-8. PubMed ID: 10594398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research.
    Fehnel SE; Ervin CM; Carson RT; Rigoni G; Lackner JM; Coons SJ;
    Value Health; 2017 Apr; 20(4):618-626. PubMed ID: 28408004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
    Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome.
    Mangel AW; Hahn BA; Heath AT; Northcutt AR; Kong S; Dukes GE; McSorley D
    J Int Med Res; 1998; 26(2):76-81. PubMed ID: 9602985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
    Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M
    Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
    Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Irritable bowel syndrome with constipation and functional constipation in adults: Treatment (Part 2 of 2)].
    Mearin F; Ciriza C; Mínguez M; Rey E; Mascort JJ; Peña E; Cañones P; Júdez J;
    Semergen; 2017 Mar; 43(2):123-140. PubMed ID: 28189496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials.
    Saps M; van Tilburg MA; Lavigne JV; Miranda A; Benninga MA; Taminiau JA; Di Lorenzo C
    Neurogastroenterol Motil; 2016 Nov; 28(11):1619-1631. PubMed ID: 27477090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.
    Madisch A; Holtmann G; Plein K; Hotz J
    Aliment Pharmacol Ther; 2004 Feb; 19(3):271-9. PubMed ID: 14984373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.
    Kim HJ; Camilleri M; McKinzie S; Lempke MB; Burton DD; Thomforde GM; Zinsmeister AR
    Aliment Pharmacol Ther; 2003 Apr; 17(7):895-904. PubMed ID: 12656692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.
    Jailwala J; Imperiale TF; Kroenke K
    Ann Intern Med; 2000 Jul; 133(2):136-47. PubMed ID: 10896640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irritable bowel syndrome and psychiatric illness.
    Walker EA; Roy-Byrne PP; Katon WJ
    Am J Psychiatry; 1990 May; 147(5):565-72. PubMed ID: 2183631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.